Study of therapeutic drugs on molecular targets in rheumatoid arthritis

Chinese Pharmacological Bulletin

Volumn 22, Issue 11, 2006, Pages 1291-1296

  Zhang, Ling Ling ^a   Wei, Wei ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Drugs; Molecular target; Rheumatoid arthritis; Signaling pathways

Indexed keywords

ADALIMUMAB; CELL ANTIGEN; CYCLIC AMP; CYTOKINE RECEPTOR ANTAGONIST; ETANERCEPT; GLUCOSIDE; GUANINE NUCLEOTIDE BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LEFLUNOMIDE; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; NONSTEROID ANTIINFLAMMATORY AGENT; PAEONIA RADIX; PROTEIN INHIBITOR; RAS PROTEIN; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL PROLIFERATION; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE COURSE; DRUG MECHANISM; HUMAN; MEDICAL EDUCATION; PROPHYLAXIS; PROTEIN TARGETING; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID; TREATMENT OUTCOME;

EID: 33847013747     PISSN: 10011978     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Lee S J, Kavanaugh A. Pharmacological treatment of established rheumatoid arthritis[J]. Best Pract Res Clin Rheumatol,2003,17 (5):811-29.
2. Dai M, Wei W. Research progress of signal transduction mechanism of synoviocytes with rheumatoid arthritis. Chin Pharmacol Bull,2003, 19(5):481-5.
3. Wu L, Wei W. Angiogenesis in rheumatoid arthritis. Chin Pharmacol Bull,2004,20(10):1098-102.
4. Atzeni F, Turiel M, Capsoni F, et al. Autoimmunity and Anti-TNF-{alpha} Agents[J]. Ann N Y Acad Sci,2005,1051:559-69.
5. Garfield B E, Krahl T, Appel S, et al. Regulation of p38 MAP kinase in CD4(+) lymphocytes by infliximab therapy in patients with rheumatoid arthritis[J]. Clin Immunol,2005,116(2):101-7.
6. Vigna P M, Abud M C, Portillo S H, et al. Immune effects of therapy with Adalimumab in patients with rheumatoid arthritis[J]. Clin Exp Immunol,2005,141(2):372-80.
7. Ranganathan P. Pharmacogenomics of tumor necrosis factor antagonists in rheumatoid arthritis [J]. Pharmacogenomics, 2005, 6 (5):481-90.
8. Horai R, Nakajima A, Habiro K, et al. TNF-alpha is crucial for the development of autoimmune arthritis in IL-1 receptor antagonist-deficient mice[J]. J Clin Invest,2004,114(11):1603-11.
9. Fleischmann R, Stern R, Iqbal I. Anakinra; an inhibitor of IL-1 for the treatment of rheumatoid arthritis[J]. Expert Opin Biol Ther,2004, 4(8):1333-44.
10. Vila A T, Puig L, Laiz A M, et al. Adverse cutaneous reactions to anakinra in patients with rheumatoid arthritis: clinicopathological study of five patients [J]. Br J Dermatol,2005,153(2):417-23.
11. Smeets R L, Joosten L A, Arntz O J, et al. Soluble interleukin-1 receptor accessory protein ameliorates collagen-induced arthritis by a different mode of action from that of interleukin-1 receptor antagonist[J]. Arthritis Rheum,2005,52(7):2202-11.
12. Woo P, Wilkinson N, Prieur A M, et al. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement[J]. Arthritis Res Ther,2005,7(6):R1281-8.
13. Nishimoto N, Mihara M. MRA for therapy of rheumatoid arthritis Nippon Rinsho,2005,63(Suppl 1):538-43.
14. Zwerina J, Redlich K, Schett G, et al. Pathogenesis of rheumatoid arthritis; targeting cytokines[J]. Ann N Y Acad Sci,2005,1051: 716-29.
15. Bradfield P F, Amft N, Vernon W E, et al. Rheumatoid fibroblast-like synoviocytes overexpress the chemokine stromal cell-derived factor1 (CXCL12), which supports distinct patterns and rates of CD4 + and CD8 + T cell migration within synovial tissue [J]. Arthritis Rheum,2003,48(9):2472-82.
16. Kremer J M, Dougados M, Emery P, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial[J]. Arthritis Rheum,2005,52(8):2263 -71.
17. Kimby E. Tolerability and safety of rituximab (MabThera R)[J]. Cancer Treat Rev,2005,31(6):456-73.
18. Morel J, Audo R, Hahne M, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kineses and phosphatidylinositol 3-kinase/Akt[J]. J Biol Chem, 2005,280(16): 15709-18.
19. Herman S, Zurgil N, Deutsch M. Low dose methotrexate induces apoptosis with reactive oxygen species involvement in T lymphocytic cell lines to a greater extent than in monocytic lines[J]. Inflamm Res,2005,54(7): 273-80.
20. Gaillard P, Jeanclaude E I, Ardissone V, et al. Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase[J]. J Med Chem,2005,48(14):4596-607.
21. Kalden J R, Antoni C, Combe B, et al. Use of combination of leflunomide with biological agents in treatment of rheumatoid arthritis [J]. J Rheumatol,2005,32(8):1620-31.
22. Zheng Y Q, Wei W. Total glucosides of paeony suppresses adjuvant arthritis in rats and intervenes cytokine-signaling between different types of synoviocytes [J]. Int Immunopharmacol,2005,5 (10):1560-73.
23. Qun C, Wei W. Effects and mechanisms of glucosides of chaenomeles speciosa on collagen-induced arthritis in rats. International Immunopharmacology,2003,3(4):593-608.
24. Dai M, Wei W, Shen Y X, et al. Glucosides of Chaenomeles speciosa remit rat adjuvant arthritis by inhibiting synoviocyte activities [J]. Acta Pharmacol Sin,2003,24(11):1161-6.
25. Takahashi H, Kato K, Miyake K, et al. Adeno-associated virus vector-mediated anti-angiogenic gene therapy for collagen-induced arthritis in mice[J]. Clin Exp Rheumatol, 2005,23(4):455-61.
26. Adriaansen J, Vervoordeldonk M J, Vanderbyl S, et al. A novel approach for gene therapy: engraftment of fibroblasts containing the artificial chromosome expression system at the site of inflammation[J]. J Gene Med,2006,8(1):63-71.